ESMO (European Society for Medical Oncology) recommendations published in 2018 allow the use of immunotherapy based on PD-1-, PD-L1-, or CTLA-4-blocking antibodies in selected patients, noting that it may lead to exacerbation of the symptoms of autoimmune disease, requiring the use of immunosuppressive treatment (21). The gene discussed is CTLA4; the disease is autoimmune disease.